PharmTech Drug Digest 11.20
News|Articles|October 9, 2018

Presentation on the Manufacture of Highly Potent Oral Solid-Dosage Forms

At CPhI Worldwide 2018, Tom Wilson, vice president of Contract Manufacturing Operations for Pfizer Global Supply and Pfizer CentreOne Contract Manufacturing, will discuss best practices for meeting manufacturing challenges of compliance as requirements shift.

As drugs in development become more potent, regulatory expectations change, forcing manufacturers to adapt.

Tom Wilson, vice president of Contract Manufacturing Operations for Pfizer Global Supply and Pfizer CentreOne Contract Manufacturing, will discuss best practices for meeting the challenges of compliance as requirements shift using Pfizer’s Newbridge, Ireland, facility as a model.

As vice president of Contract Manufacturing Operations for Pfizer Global Supply (PGS) and Pfizer CentreOne Contract Manufacturing, Wilson serves as manufacturing liaison between the two organizations. In previous roles, he led Pfizer Optionality Program for PGS, as well as the integration team for Hospira Device Operations; oversaw management of Pfizer’s Alliance External Suppliers worldwide; and provided counsel on Pfizer’s global manufacturing strategy. He joined Pfizer in 2010 with the acquisition of Wyeth, where he was vice president of Product Operations.

This insight briefing will take place at CPhI Worldwide in Madrid, Spain, on Wednesday, Oct. 10, 2018, 1:10pm–1:40pm at the ICSE Theatre, Hall 1, stand 1G90.

Source: CPhI


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.